A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2

By sjmartinez • February 27, 2024

Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, Davey RT Jr, Lye DC, Dodd LE, Yang OO, Benson CA, Deye GA, Doernberg SB, Hynes NA, Grossberg R, Wolfe CR, Nayak SU, Short WR, Voell J, Potter GE, Rapaka RR. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Ann Intern Med. 2024 Feb 27. doi: 10.7326/M23-2593. Epub ahead of print. PMID: 38408357.

Tags: Infectious Diseases, Publications

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response

Gu Y, Singh S, Alqarihi A, Alkhazraji S, Gebremariam T, Youssef EG, Liu H, Fan X, Jiang WR, Andes D, Cochrane TR, Schwartz JA, Filler[...]

Leveraging near-real-time patient and population data to incorporate fluctuating risk of severe COVID-19: development and prospective validation of a personalised risk prediction tool

Swinnerton K, Fillmore NR, Vo A, La J, Elbers D, Brophy M, Do NV, Monach PA, Branch-Elliman W. Leveraging near-real-time patient and population data to[...]

Variability of antimicrobial susceptibility of commensal Neisseria species supports its use as a marker of excessive antimicrobial consumption – reflections from the results of a four-country study

Kanesaka I, Foschi C, Marangoni A, Adamson PC, Klausner J, Dong HV, Vanbaelen T, De Baetselier I, de Block T, Manoharan-Basil SS, Kenyon C. Variability[...]